Exact Mass: 482.0769

Exact Mass Matches: 482.0769

Found 33 metabolites which its exact mass value is equals to given mass value 482.0769, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

2,3-(S)-hexahydroxydiphenoyl-D-glucose

2,3-(S)-hexahydroxydiphenoyl-D-glucose

C20H18O14 (482.0697)


   

3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0(2),.0(1),(1)]tricosa-1(23),2,4,6,19,21-hexaene-8,18-dione

3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0(2),.0(1),(1)]tricosa-1(23),2,4,6,19,21-hexaene-8,18-dione

C20H18O14 (482.0697)


   

6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0,.0(1),(1)]tricosa-4,6,8,10,12,14-hexaene-3,16-dione

6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0,.0(1),(1)]tricosa-4,6,8,10,12,14-hexaene-3,16-dione

C20H18O14 (482.0697)


   

Regorafenib

4-(4-(((4-chloro-3-(Trifluoromethyl)phenyl)carbamoyl)amino)-3-fluorophenoxy)-N-methylpyridine-2-carboxamide

C21H15ClF4N4O3 (482.0769)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].

   

2-(alpha-Hydroxypropyl)thiamine diphosphate; 2-Hydroxypropyl-ThPP

2-(alpha-Hydroxypropyl)thiamine diphosphate; 2-Hydroxypropyl-ThPP

C15H24N4O8P2S (482.079)


   

degalloyl-punicacortein A

degalloyl-punicacortein A

C20H18O14 (482.0697)


   

4,6-(S)-HHDP-D-glucose|4,6-O-((S)-4,4,5,5,6,6-hexahydroxydiphenoyl)-D-glucose|4,6-O-<(S)-4,4,5,5,6,6-hexahydroxydiphenoyl>-D-glucose

4,6-(S)-HHDP-D-glucose|4,6-O-((S)-4,4,5,5,6,6-hexahydroxydiphenoyl)-D-glucose|4,6-O-<(S)-4,4,5,5,6,6-hexahydroxydiphenoyl>-D-glucose

C20H18O14 (482.0697)


   

Fucodiphlorethol C

Fucodiphlorethol C

C24H18O11 (482.0849)


   

fucodiphloroethol G

fucodiphloroethol G

C24H18O11 (482.0849)


   

Regorafenib (BAY 73-4506)

Regorafenib (BAY 73-4506)

C21H15ClF4N4O3 (482.0769)


   

(-)-1 6-BIS(2-CHLOROPHENYL)-1 6-DIPHENY&

(-)-1 6-BIS(2-CHLOROPHENYL)-1 6-DIPHENY&

C30H20Cl2O2 (482.084)


   

(-)-1,2-BIS((2S,5S)-2,5-DIETHYLPHOSPHOLANO)ETHANE

(-)-1,2-BIS((2S,5S)-2,5-DIETHYLPHOSPHOLANO)ETHANE

C30H20Cl2O2 (482.084)


   

3-bromo-7,12-diphenylbenzo[k]fluoranthene

3-bromo-7,12-diphenylbenzo[k]fluoranthene

C32H19Br (482.067)


   
   

(2-NAPHTHYLMETHYL)(TRIPHENYL)PHOSPHONIUM BROMIDE

(2-NAPHTHYLMETHYL)(TRIPHENYL)PHOSPHONIUM BROMIDE

C29H24BrP (482.0799)


   

2-(4-(2-((3-(5-(Pyridin-2-Ylthio)thiazol-2-Yl)ureido)methyl)-1h-Imidazol-4-Yl)phenoxy)acetic Acid

2-(4-(2-((3-(5-(Pyridin-2-Ylthio)thiazol-2-Yl)ureido)methyl)-1h-Imidazol-4-Yl)phenoxy)acetic Acid

C21H18N6O4S2 (482.0831)


   

Regorafenib

Regorafenib

C21H15ClF4N4O3 (482.0769)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor C274 - Antineoplastic Agent > C1742 - Angiogenesis Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Regorafenib (BAY 73-4506) is an orally active and potent multi-targeted receptor tyrosine kinase inhibitor, with IC50 values of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively. Regorafenib shows very robust antitumor and antiangiogenic activity[1].

   

2,3-Dihydroxybenzoyl 5-adenylate(1-)

2,3-Dihydroxybenzoyl 5-adenylate(1-)

C17H17N5O10P- (482.0713)


Conjugate base of 2,3-dihydroxybenzoyl 5-adenylate.

   

(3,4-Dihydroxybenzoate)adenylate

(3,4-Dihydroxybenzoate)adenylate

C17H17N5O10P- (482.0713)


   

(10r,11r,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione

(10r,11r,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione

C20H18O14 (482.0697)


   

(10r,11s,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione

(10r,11s,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione

C20H18O14 (482.0697)


   

2,3-hexahydroxydiphenyl-D-glucose

NA

C20H18O14 (482.0697)


{"Ingredient_id": "HBIN004100","Ingredient_name": "2,3-hexahydroxydiphenyl-D-glucose","Alias": "NA","Ingredient_formula": "C20H18O14","Ingredient_Smile": "C1=C2C(=C(C(=C1O)O)O)C3=C(C(=C(C=C3C(=O)OC4C(C(C(OC4O)CO)O)OC2=O)O)O)O","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "42628","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}

   

2,3-o-(s)-hexahydroxydiphenoyl-d-gluco-pyranose

NA

C20H18O14 (482.0697)


{"Ingredient_id": "HBIN004147","Ingredient_name": "2,3-o-(s)-hexahydroxydiphenoyl-d-gluco-pyranose","Alias": "NA","Ingredient_formula": "C20H18O14","Ingredient_Smile": "C1=C2C(=C(C(=C1O)O)O)C3=C(C(=C(C=C3C(=O)OC4C(C(C(OC4O)CO)O)OC2=O)O)O)O","Ingredient_weight": "482.3 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15749","TCMID_id": "9501","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "14035453","DrugBank_id": "NA"}

   

(10s,11r,12r,13r,15r)-3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0²,⁷.0¹⁰,¹⁵]tricosa-1(19),2,4,6,20,22-hexaene-8,18-dione

(10s,11r,12r,13r,15r)-3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0²,⁷.0¹⁰,¹⁵]tricosa-1(19),2,4,6,20,22-hexaene-8,18-dione

C20H18O14 (482.0697)


   

5'-[2,4-dihydroxy-6-(2,4,6-trihydroxyphenoxy)phenoxy]-[1,1'-biphenyl]-2,3',4,6-tetrol

5'-[2,4-dihydroxy-6-(2,4,6-trihydroxyphenoxy)phenoxy]-[1,1'-biphenyl]-2,3',4,6-tetrol

C24H18O11 (482.0849)


   

[(6s,8as)-8a-(chloromethyl)-8-hydroxy-1-methyl-2,5-dioxo-3h,6h-imidazo[1,2-a]pyrazin-6-yl]methyl 2,3-dihydroxy-2-(hydroxymethyl)-1,4-benzoxazine-5-carboxylate

[(6s,8as)-8a-(chloromethyl)-8-hydroxy-1-methyl-2,5-dioxo-3h,6h-imidazo[1,2-a]pyrazin-6-yl]methyl 2,3-dihydroxy-2-(hydroxymethyl)-1,4-benzoxazine-5-carboxylate

C19H19ClN4O9 (482.0841)


   

3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0²,⁷.0¹⁰,¹⁵]tricosa-1(19),2,4,6,20,22-hexaene-8,18-dione

3,4,5,11,12,13,21,22,23-nonahydroxy-9,14,17-trioxatetracyclo[17.4.0.0²,⁷.0¹⁰,¹⁵]tricosa-1(19),2,4,6,20,22-hexaene-8,18-dione

C20H18O14 (482.0697)


   

3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(22),2(7),3,5,18,20-hexaene-8,17-dione

3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(22),2(7),3,5,18,20-hexaene-8,17-dione

C20H18O14 (482.0697)


   

(1s,19r,21s,22r,23r)-6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0⁴,⁹.0¹⁰,¹⁵]tricosa-4,6,8,10(15),11,13-hexaene-3,16-dione

(1s,19r,21s,22r,23r)-6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0⁴,⁹.0¹⁰,¹⁵]tricosa-4,6,8,10(15),11,13-hexaene-3,16-dione

C20H18O14 (482.0697)


   

(14s,15r,19r)-2,3,4,7,8,9,19-heptahydroxy-14-[(1r,2r)-1,2,3-trihydroxypropyl]-13,16-dioxatetracyclo[13.3.1.0⁵,¹⁸.0⁶,¹¹]nonadeca-1,3,5(18),6(11),7,9-hexaene-12,17-dione

(14s,15r,19r)-2,3,4,7,8,9,19-heptahydroxy-14-[(1r,2r)-1,2,3-trihydroxypropyl]-13,16-dioxatetracyclo[13.3.1.0⁵,¹⁸.0⁶,¹¹]nonadeca-1,3,5(18),6(11),7,9-hexaene-12,17-dione

C20H18O14 (482.0697)


   

2,3,4,7,8,9,19-heptahydroxy-14-(1,2,3-trihydroxypropyl)-13,16-dioxatetracyclo[13.3.1.0⁵,¹⁸.0⁶,¹¹]nonadeca-1,3,5(18),6(11),7,9-hexaene-12,17-dione

2,3,4,7,8,9,19-heptahydroxy-14-(1,2,3-trihydroxypropyl)-13,16-dioxatetracyclo[13.3.1.0⁵,¹⁸.0⁶,¹¹]nonadeca-1,3,5(18),6(11),7,9-hexaene-12,17-dione

C20H18O14 (482.0697)


   

6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0⁴,⁹.0¹⁰,¹⁵]tricosa-4,6,8,10(15),11,13-hexaene-3,16-dione

6,7,8,11,12,13,21,22,23-nonahydroxy-2,17,20-trioxatetracyclo[17.3.1.0⁴,⁹.0¹⁰,¹⁵]tricosa-4,6,8,10(15),11,13-hexaene-3,16-dione

C20H18O14 (482.0697)


   

(10r,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione

(10r,13r,14r,15s)-3,4,5,11,14,20,21,22-octahydroxy-13-(hydroxymethyl)-9,12,16-trioxatetracyclo[16.4.0.0²,⁷.0¹⁰,¹⁵]docosa-1(18),2,4,6,19,21-hexaene-8,17-dione

C20H18O14 (482.0697)